Venlafaxine extended release (ER) in the treatment of generalised anxiety disorder: twenty-four-week placebo-controlled dose-ranging study.
about
World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Posttraumatic Stress DisordersAntidepressants for generalised anxiety disorder (GAD)Antidepressants for generalised anxiety disorder (GAD)Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disordersQuetiapine monotherapy in acute treatment of generalized anxiety disorder: a systematic review and meta-analysis of randomized controlled trialsManagement of generalized anxiety disorder in primary care: identifying the challenges and unmet needs.A psychopharmacological treatment algorithm for generalised anxiety disorder (GAD)A double-blind, randomised, placebo controlled study of venlafaxine XL in patients with generalised anxiety disorder in primary care.Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology.Advances in the treatment of depressionExtended-release formulation of venlafaxine in the treatment of post-traumatic stress disorder.Pregabalin for the treatment of generalized anxiety disorder: a novel pharmacologic intervention.Serotonin noradrenaline reuptake inhibitors: A new generation of treatment for anxiety disorders.Efficacy and safety of duloxetine in the treatment of older adult patients with generalized anxiety disorder: a randomized, double-blind, placebo-controlled trialWorld Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders - first revision.Information for physicians and pharmacists about drugs that might cause dry mouth: a study of monographs and published literature.Remission with venlafaxine extended release or selective serotonin reuptake inhibitors in depressed patients: a randomized, open-label studyThe safety of SSRIs in generalised anxiety disorder: any reason to be anxious?Development of SPECT imaging agents for the norepinephrine transporters: [123I]INERA Review of the Diagnosis, Pharmacologic Treatment, and Economic Aspects of Anxiety Disorders.Paroxetine in the treatment of generalised anxiety disorder.Treatment-resistant panic disorder.The efficacy of antidepressants for generalized anxiety disorder: a systematic review and meta-analysis.Escitalopram in the treatment of generalized anxiety disorder.A double-blind, randomized, placebo-controlled, fixed-dose phase III study of vilazodone in patients with generalized anxiety disorderTreatment of anxiety disorders with venlafaxine XR.Emerging treatments for depression.The diagnosis and treatment of generalized anxiety disorder.Establishing non-inferiority in treatment trials in psychiatry: guidelines from an Expert Consensus Meeting.The effects of venlafaxine and cognitive behavioral therapy alone and combined in the treatment of co-morbid alcohol use-anxiety disorders.Validating the inhalation of 7.5% CO(2) in healthy volunteers as a human experimental medicine: a model of generalized anxiety disorder (GAD).Evidence-based review of clinical outcomes of guideline-recommended pharmacotherapies for generalized anxiety disorder.The cost effectiveness of pharmacological treatments for generalized anxiety disorder.Onset of activity and time to response on individual CAPS-SX17 items in patients treated for post-traumatic stress disorder with venlafaxine ER: a pooled analysis.Two Formulations of Venlafaxine are Bioequivalent when Administered as Open Capsule Mixed with Applesauce to Healthy Subjects.Cost-effectiveness of psychological and pharmacological interventions for generalized anxiety disorder and panic disorder.The best next drug in the course of generalized anxiety disorders: the "PN-GAD-algorithm".Meta-analysis: Risk of hyperhidrosis with second-generation antidepressants.Sertraline in generalized anxiety disorder: efficacy in treating the psychic and somatic anxiety factors.An effect-size analysis of pharmacologic treatments for generalized anxiety disorder.
P2860
Q22305681-0A562C4C-8CE9-4304-9A3D-6C8078DB96E5Q24186057-1D458046-E0FA-4431-A4EA-1CD0937B8922Q24248715-97EBD6E7-352C-4364-872D-6DCCEA16DB53Q27009995-65F596AC-645B-4379-B023-BE9BB86BCCDCQ28069524-2F7850B8-2ED6-42BD-A3E9-76F9B1F1BCCCQ34024109-9F441F29-2282-4029-8DAF-4CE6B67D09CEQ34183517-F34B2973-BFD3-4A74-BFFB-59C2CC069E87Q34224290-9DE5CA79-A7C4-4C5F-A624-7E24C997A3A6Q34465555-10D2819A-6346-44D6-B324-0FE1D751954AQ34496251-D3393943-24F4-460C-B34B-4A220A988D92Q34636674-DBBCD619-A9F2-4CDC-8C5C-AE81B7A6628BQ34645876-F32F0E91-6C08-4308-A02B-65E6E78BC3F9Q34662418-81977C06-61FA-4C1F-9314-A5A1E7094A5BQ34853281-3E59F66D-D272-4E34-9420-4363F4C1BE40Q34865036-3BD24088-02E9-47E4-BFF2-8F2567A2E631Q35057288-52B41FC1-7F4D-4DC8-A6A8-6435542EB95DQ35062660-3917BDCB-F0D2-412F-A0A4-4DD7321D8917Q35208413-3E5E7DF4-3E32-4133-804F-0D0ABB3CDB44Q35654951-2935E5BF-BE5F-4E9E-A935-D83C9B2FB689Q35666166-43994DF0-5ABC-4B89-ACEE-DF48039EF621Q35841600-1ECDD7AE-F48A-48D4-B698-EBBC67138E7DQ35901886-C411CA09-0656-41E8-9349-107491D738DBQ36114391-07B0A187-953E-4DC6-815D-948A2BC70BB9Q36198579-504A3691-B460-49E0-9568-0D000A3AF894Q36366194-519407BE-FAB4-4AA6-A5C2-01CABF803BF1Q36419538-79B191B3-9C20-4E04-86AA-6BE1125C0809Q36655168-C509A1CB-F67E-463B-A065-CDF75E57569EQ36837462-13D64097-0118-43E6-B5E2-0A5E2A27142EQ37219387-A8F6B7CA-BB90-41C9-AE67-C508263091A3Q37694597-250E1B6B-C01B-47D9-8B87-7460ABC4E780Q37945155-3343A6F9-C307-4CE9-8E85-922332F751EFQ38031324-5AF0AB44-1429-4806-A19A-4261D87FAA66Q38091323-3EE02B6F-18DF-4686-8BE9-4C1611DBE729Q40082557-2151B7FA-8BF2-4A35-BBB7-43DCD286A45CQ42096559-24E4C472-5F7D-4BBD-B1F2-2E674473C709Q45009855-3E469C73-B4F0-4733-B783-849E67E7EA56Q45159165-5C514CF5-56F0-4443-B3E7-EB5766A6016BQ46182025-BD7197A6-85A9-4208-AED7-7E5313810493Q46475730-A426CFCB-0BF6-42BB-8C80-6E4FC1926950Q46913592-4C324594-3F53-402F-B2C9-1DA0D473AFED
P2860
Venlafaxine extended release (ER) in the treatment of generalised anxiety disorder: twenty-four-week placebo-controlled dose-ranging study.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
Venlafaxine extended release ( ...... controlled dose-ranging study.
@en
type
label
Venlafaxine extended release ( ...... controlled dose-ranging study.
@en
prefLabel
Venlafaxine extended release ( ...... controlled dose-ranging study.
@en
P2093
P356
P1476
Venlafaxine extended release ( ...... controlled dose-ranging study.
@en
P2093
Allgulander C
P356
10.1192/BJP.179.1.15
P407
P577
2001-07-01T00:00:00Z